News
CBD capsules could treat Alzheimer’s and other neurological disorders
Researchers have developed oral capsules that improved the delivery of CBD into the brain by up to 40-times.
Tiny capsules of CBD could help treat neurological disorders such Alzheimer’s disease and multiple sclerosis, say researchers.
A team from from Curtin University has developed tiny oral capsules that improved the delivery of CBD into the brain by up to 40-times.
The technology has the potential to treat neurological disorders such as Alzheimer’s disease, multiple sclerosis and traumatic brain injuries.
The research, funded by Zelira Therapeutics saw the research team create tiny capsules containing cannabinoids which, when taken orally, were absorbed by the body faster and penetrated the brain quicker in mice models with neurological diseases, than when delivered in liquid form.
Lead researcher, associate professor Ryu Takechi from the Curtin Health Innovation Research Institute (CHIRI) and the School of Population Health, said there has been a growing interest in the use of CBD to treat various neurological diseases, but there were limitations due to its poor absorption and sensitivity to light and stomach acid when consumed orally.
He commented: “With this new capsulated form, we were able to improve the brain delivery of CBD remarkably by 40 times in animal models and we were also able to protect the drug from oxidation and degradation by light, which helps extend product shelf-life.”
He added that the findings “may be helpful in supporting the clinical use of medicinal cannabis in the treatment of neurological disorders.”
Dr Oludare Odumosu, Zelira’s CEO said: “The new encapsulation technology significantly improves the efficiency with which cannabinoid-based drugs can be delivered into the brain and presents a game changing platform to improve the effectiveness of cannabinoid therapies for neurological disorders while reducing cost and enhancing safety.”
Takechi and his team are currently using the encapsulation technology to assess the efficacy of CBD to protect from and prevent cognitive decline in diabetes, with results expected to be reported later in the year.
-
News6 months agoEurope’s first legal cannabis dispensaries to open under sixth Swiss pilot
-
Science5 months agoMedical cannabis doesn’t impair cognitive function – study
-
Industry6 months agoFirst Jersey-grown medicinal cannabis product to hit UK market
-
News6 months agoFive years of medical cannabis, five NHS prescriptions – how did we get here?
-
News5 months agoJapan takes major step towards cannabis reform
-
Health5 months agoUK data links medical cannabis to improvements in ADHD patients
-
News5 months agoMPs call for children with epilepsy to get medical cannabis on NHS
-
Health3 months agoUK researchers publish first findings on cannabis and Long COVID
